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Nonresolving inflammation expands a heterogeneous
population of myeloid suppressor cells capable of
inhibiting T cell function. This heterogeneity has
confounded the functional dissection of individual
myeloid subpopulations and presents an obstacle
for antitumor immunity and immunotherapy. Using
genetic manipulation of cell death pathways, we
found the monocytic suppressor-cell subset, but not
the granulocytic subset, requires continuous c-FLIP
expression to prevent caspase-8-dependent, RIPK3-
independent cell death. Development of the granu-
locyte subset requires MCL-1-mediated control of
the intrinsic mitochondrial death pathway. Monocytic
suppressors tolerate the absence of MCL-1 provided
cytokines increase expression of the MCL-1-related
protein A1. Monocytic suppressors mediate T cell
suppression, whereas their granulocytic counterparts
lacksuppressive function. The lossof thegranulocytic
subset via conditional MCL-1 deletion did not alter
tumor incidence implicating the monocytic compart-
ment as the functionally immunosuppressive subset
in vivo. Thus, death pathway modulation defines the
development, survival, and function of myeloid sup-
pressor cells.
INTRODUCTION
Nonresolving inflammation is caused by failure to eliminate a
long-lived insulting entity including persisting microbes, im-
planted medical devices, cholesterol and fat in atherosclerosis
and obesity, and self-antigens driving chronic autoinflamma-Ition (Nathan and Ding, 2010). In cancer, nonresolving inflam-
mation is driven by the growing malignancy and is associated
with the production of large numbers of mature and immature
myeloid cells from the bone marrow (BM). Circulating imma-
ture myeloid cells with immunosuppressive functions are
collectively called myeloid-derived suppressor cells (MDSCs),
and are negatively correlated with cancer outcomes (Gabrilo-
vich et al., 2012; Wu et al., 2014). MDSC expansion is related
to a hematopoietic response to inflammation where growth
factors such as GM-CSF and G-CSF signal to the BM to tran-
siently increase cellular output. This ‘‘emergency’’ hematopoi-
esis aids in the destruction and elimination of the insulting
entity and is followed by tissue repair and resolution (Manz
and Boettcher, 2014). In nonresolving inflammation, the
inciting agent remains and the hematopoietic cycle linked to
clearance and resolution becomes dysregulated. MDSCs
have attracted attention in cancer biology because they are
linked with suppression of lymphocyte activation. The number
and activity of cytotoxic CD8+ T cells are correlated with anti-
tumor immunity (Gajewski et al., 2013; Galon et al., 2013).
Therapies designed to elicit antitumor T cell responses must
overcome or bypass the local MDSC-mediated immune sup-
pression inside the tumor microenvironment (Motz and Cou-
kos, 2013; Restifo et al., 2012).
The current understanding of MDSC development, lifespan,
and function has been limited by heterogeneity of the myeloid
populations produced from the BM under inflammatory stress
(Gabrilovich et al., 2007; Gabrilovich and Nagaraj, 2009; Gabrilo-
vich et al., 2012; Wu et al., 2014). Thus, it remains unclear which
type of MDSC to target and which MDSC subpopulation(s)
contributes to immunosuppression. MDSCs express combina-
tions of myeloid-associated cell-surface markers and have an
immature myeloid phenotype, but their hallmark functional char-
acteristic is their ability to suppress T cells. (Gabrilovich et al.,
2007; Peranzoni et al., 2010; Schouppe et al., 2013; Talmadge
and Gabrilovich, 2013; Youn et al., 2012). MDSCs comprisemmunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc. 947
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monocyte-macrophages, and more primitive cells such as
band-form granulocytic precursors (Gabrilovich et al., 2007; Ga-
brilovich and Nagaraj, 2009; Movahedi et al., 2008; Youn et al.,
2012). So far, there is no accepted marker system to predict
whether a MDSC will be suppressive without evaluating its sup-
pressive function using in vitro T cell assays. However, the pres-
ence of activated T cells or local inflammatory milieus engenders
changes in MDSCs and alters their functional activity (Haver-
kamp et al., 2011). Thus, functional dissection of MDSCs is a
type of ‘‘Schro¨dinger’s Cat’’ scenario where suppression is
monitored using an assay that induces the functional property
for which it is testing (Haverkamp et al., 2011). Because the
specific MDSC subpopulations required for T cell suppression
remains controversial, efforts to engineer MDSCs have not yet
advanced to the point at which a defined cell type is used ther-
apeutically (Highfill et al., 2010; Yin et al., 2010). Similarly, inhib-
iting the key suppressive subtype(s) of MDSCs to enhance T cell
function might be an avenue to improve antitumor immunity via
interruption of the tumor-induced immunosuppressive milieu
(Gajewski et al., 2013; McAllister and Weinberg, 2014; Restifo
et al., 2012).
In the mouse, most studies focus on the accumulation of
CD11b+Gr-1+ cells in the blood, spleen, and local inflammatory
site, and human MDSC counterparts have been defined (Tal-
madge and Gabrilovich, 2013). Murine MDSCs are further
subdivided by surface expression of Ly6C and Ly6G. Granulo-
cytic MDSC are Ly6G+, Ly6C+, whereas monocytic MDSC
(mixtures of immature monocytes, macrophages, and mono-
cyte-derived dendritic cells) are Ly6Glo, Ly6C+. Based on
these and other markers including F4/80, CD115, and IL-
4Ra, elaborate strategies have been used to separate MDSCs,
and both granulocytic (referred to here as PMN-MDSC)
and monocytic (Mo-MDSC) MDSCs have demonstrated
immunosuppressive properties. However, further examination
into the function of these cells has been impeded given that
MDSC cell-surface markers have overlapping expression
with other cell types and no transcription factor deficiencies
have yet been described to ablate specific MDSC subpopula-
tions (Gabrilovich and Nagaraj, 2009; Movahedi et al., 2008;
Priceman et al., 2010; Schouppe et al., 2013; Youn et al.,
2012). Thus heterogeneity is an inherent hurdle toward under-
standing the role of regulatory myeloid cells in chronic inflam-
mation. To overcome this obstacle, we sought to define MDSC
subpopulations using properties of intrinsic and extrinsic cell
death pathways involved in myeloid lineage development
and survival. Herein we demonstrated the hierarchy of cell
death pathways required for the development, survival, and
function of MDSCs, and define monocytic MDSCs as the
dominant immunosuppressive subset. Further, we demon-
strated that the antiapoptotic molecule c-FLIP is constitutively
required for the development of Mo-MDSCs and that the in-
duction of the MCL-1-related antiapoptotic A1 (three closely
related A1 isoforms are encoded by Bcl2a1a, Bcl2a1b, and
Bcl2a1c) by GM-CSF further promotes their survival. In
contrast, PMN-MDSCs require a different antiapoptotic mole-
cule MCL-1 for development, and the loss of granulocytes
through conditional MCL-1 ablation does not contribute to tu-
mor growth or incidence.948 Immunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc.RESULTS
Genetic Manipulation of Death Pathways Skews
Suppressor Populations
Immature monocytic (Mo) and granulocytic (PMN) cells can be
expanded in vitro from BM myeloid precursors with interleukin-
6 (IL-6) and GM-CSF (Marigo et al., 2010). Like MDSCs isolated
from spleens of cancer-bearing mice (Ugel et al., 2012), BM
myeloid cells grown in GM-CSF and IL-6 exhibit a continuum
of Ly6C and Ly6G expression (Figure 1A). Hereafter we refer to
in vitro-generated populations of cells expanded from the BM
as ‘‘myeloid suppressors’’ (MS) to avoid contention with specific
definitions of in vivo MDSCs accumulating in nonresolving
inflammation (Gabrilovich et al., 2007; Talmadge and Gabrilo-
vich, 2013). We harnessed previous observations about the
role of extrinsic death receptor mediated and intrinsic mitochon-
drial antiapoptotic pathways in regulating the development of
myeloid lineages and devised a ‘‘mirror image’’ genetic system
to generate MS cultures dominated by either the granulocytic
or monocytic populations. To generate MS depleted of granulo-
cytic lineages, we used mice bearing a conditional allele of the
antiapoptotic bcl-2 family member Mcl1 crossed to the LysM-
Cre deleter (Steimer et al., 2009). These animals (referred to as
MCL-1DM) have a near complete ablation of mature granulocytes
in tissues and blood but retain normal numbers of monocytes
and macrophages (Dzhagalov et al., 2007; Steimer et al.,
2009). BM-derived MS cultures from the MCL-1DM animals pre-
sented an enriched Ly6C+, Ly6GMo-MS fraction and reduced
PMN-MS fraction relative to controls (Figure 1A, see also Figures
S1A and S1B available online). Deletion of MCL-1 in MS cultures
was efficient, as immunoblotting showed a near complete
absence of MCL-1 protein (Figure S1C). Therefore MCL-1 abla-
tion was a means to skew MS populations such that the propor-
tion of Mo-MS in the cultures was increased relative to control
cultures.
To generate a suppressor population skewed toward PMN-
MS, we used mice lacking c-FLIP (encoded by Cflar) in the late
myeloid lineages again using the LysM-Cre deleter (c-FLIPDM).
c-FLIP is an inhibitor of the following extrinsic death pathways
controlled by death receptor (DR) signaling: caspase-8-medi-
ated apoptosis, and RIPK1 and RIPK3-mediated necroptosis
(Green et al., 2011; Newton et al., 2014). c-FLIPDMmice have hy-
perproduction of granulocytes and a relative depletion of mono-
cyte-derived macrophages (Gordy et al., 2011; Huang et al.,
2010) and, in our colony, die before weaning. BM cultures from
c-FLIPDM mice had inverse properties from the MCL-1DM MS
cultures and were enriched for Ly6G+, Ly6C+ PMN-MS (Fig-
ure 1A; Figures S1A and S1B).
Using our matched genetic systems, we investigated the
suppressive capacity of c-FLIPDM and MCL-1DM MS relative to
control MS by monitoring OVA-specific CD8+ T (OT-I) cell prolif-
eration during in vitro T cell-MS cocultures. c-FLIPDM MS had
negligible suppressive activity whileMCL-1DMMSwere enriched
for suppression on a cell-for-cell basis (Figure 1B; Figure S1D).
To determine whether the lack of inhibitory function of PMN-
MS was caused by the loss of monocytic cells in c-FLIPDM
animals, we performed experiments wherein MCL-1DM and
c-FLIPDM MS were mixed immediately prior to culture with
OT-I cells, at a fixed suppressor cell number per well. T cell
Figure 1. Death Pathways Can Be Used to Manipulate the Population Structure and Activity of MS
(A–C) BM-generated MS were grown from MCL-1DM, C57BL/6, or FLIPDMmice. (A) Flow cytometry analysis of MS cultures. Numbers indicate the percentage of
CD11b+ cells. Cytospins collected fromMS cultures. Data are representative of no fewer than ten independent experiments. (B) Suppressive function of MS was
measured using 53 105 CFSE-labeled OT-I cells cultured with titrated numbers of MS from each genotype in the presence of SIINFEKL peptide. CFSE dilution in
CD8+ cells was evaluated by flow cytometry. Gray shaded histograms show negative control wells cultured without peptide. Plots from four independent ex-
periments are shown (n = 2 for each experiment). (C) Representative plots from two independent experiments (n = 2 for each experiment) showing CFSE dilution in
in CD8+ cells cultured with MCL-1DMMSmixed with varying numbers of FLIPDMMS to a final number of 23 105 total MS (top panel) or unmixed control MCL-1DM
and FLIPDM MS (bottom panels).
(D) Diagram showing how genetics can be used to modulate the composition and suppressive function of MS subpopulations.
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of MCL-1DM MS (Figure 1C). These data demonstrate suppres-
sion is principally found in the monocytic component of the MS
pool. To further evaluate MS-mediated suppression of T cell pro-
liferation, we sorted Mo-MS and PMN-MS from wild-type (WT)
BM cultures based on CD11b-gated Ly6G and Ly6C expression
(Figure S1E). Purified Mo-MS were suppressive, with detectable
inhibitory effects on T cell proliferation even when cultured at a
1:20 MS: OT-I cell ratio. However, when OT-I cells were cultured
with PMN-MS, proliferation was inhibited, but only at the highestIratios, and lost as the number of PMN-MSwas decreased by one
dilution step (Figures S1F and S1G).
One explanation for the differences between Mo-MS and
PMN-MS in T cell suppressive activity could have been
decreased viability of the PMN-MS. We therefore evaluated the
viability of both MS populations at 24 hr intervals throughout
the duration of the T cell suppression assay. The percentage of
live cells was measured using a viability dye (V405) detecting
cell-surface amine groups, a hallmark of dead and dying cells.
Viability was equivalent between Mo-MS and PMN-MS at allmmunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc. 949
Figure 2. c-FLIP Controls Mo-MS Viability
(A) Diagram showing the role of c-FLIP in the in-
hibition of caspase-8-mediated apoptosis and
necroptosis.
(B) Flow cytometry analysis of BM-MS generated
from FLIPWT, RIPK3WT, FADDWT and c-FLIPKO,
RIPK3KO, FADDKO triple-deficient mice. Numbers
indicate the percentage of live cells (n = 3 inde-
pendent experiments).
(C) Flow cytometry analysis of BM-MS from
Cflarfl/fl; Rosa-CreERT2 mice treated with 4-OH
tamoxifen at d3 of culture. Ethanol at the same
final concentration as the 4-OH tamoxifen cultures
served as the control. Numbers indicate the per-
centage of live cells (n = 3 independent experi-
ments).
(D) Cflar was exogenously deleted by 4-OH
tamoxifen on d5 of culture using BM-MS from
Cflarfl/fl; Rosa-CreERT2 mice on a Ripk3+/ or
Ripk3/ background. Control cells received
ethanol. On d6 Mo-MS were sorted and cultured
with GM-CSF (50 ng/mL) for 24 hr, after which
viability was assessed using V405 staining.
(E) Cflar was exogenously deleted by 4-OH
tamoxifen in the presence or absence of QVD
(20 mM) on d5 of culture using BM-MS from
Cflarfl/fl; Rosa-CreERT2 mice. Control cells
received ethanol and DMSO. On d6 Mo-MS were
sorted and cultured with GM-CSF (50 ng/mL) in
the presence or absence of QVD (20 mM) for 24 hr.
Viability was assessed using V405 staining.
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proliferation even though they survive equally as well as the sup-
pressive Mo-MS (Figure S1H). Collectively, our genetic and sort-
ing strategies resolve the long-standing issue of which subset in
the MS pool is responsible for suppression of T cell proliferation,
identifying monocytic MS as the dominant suppressive popula-
tion (Figure 1D).
c-FLIP Controls the Development of Monocytic
Suppressors
c-FLIP inhibits FADD-caspase-8 apoptotic and RIPK1-RIPK3-
mediated necroptotic pathways (Figure 2A) (Green et al., 2011).950 Immunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc.Therefore if c-FLIP regulates Mo-MS sur-
vival as predicted from the c-FLIPDM
results, ablation of FADD and RIPK3
should rescueMo-MS even in a complete
c-FLIP-deficient background. Unlike c-
FLIPDM MS cultures (Figure 1A), BM
from mice lacking c-FLIP, FADD, and
RIPK3 had Mo-MS (Figure 2B). Thus c-
FLIP is important for the viability of Mo-
MS through development in vitro but
dispensable for PMN-MS. We confirmed
this conclusion by depleting c-FLIP using
tamoxifen-mediated Cre-deletion in
Cflarfl/fl; Rosa-CRE-ERT2BMMScultures
(Figure 2C). Mo-MS were absent from the
tamoxifen-treated, but not from vehicle
control cultures, while PMN-MS werepresent in all conditions, arguing that c-FLIP is dispensable for
PMN-MS but continuously required for Mo-MS.
Because c-FLIP is required to inhibit both necroptosis and
Caspase-8-mediated apoptosis, we next tested whether one
or both pathways were involved in the viability of Mo-MS. We
generated Cflarfl/fl; Rosa-CRE-ERT2 mice on a RIPK3-deficient
background. Following tamoxifen-mediated Cre-deletion, Mo-
MS died, even in GM-CSF, arguing that viability of Mo-MS is
controlled by c-FLIP inhibiting caspase-8-mediated apoptosis
rather than RIPK1-RIPK3 necroptosis (Figure 2D). Concurrent
treatment of MS cultures with the pan-caspase inhibitor QVD
at the time of tamoxifen-mediated Cflar ablation reduced cell
Immunity
Control of Myeloid Suppressors by Death Pathwaysdeath (Figure 2E). Therefore the viability of Mo-MS is controlled
by c-FLIP inhibition of caspase-8 mediated apoptosis rather
than RIPK1-RIPK3 necroptosis.
Suppressors Are Dependent on the MCL-1 – A1 Axis
Genetic experiments have shown that nearly all cells in the body
have an absolute requirement for MCL-1 (Opferman et al., 2003,
2005; Wang et al., 2013; Weber et al., 2010). Monocytic cells are
an exception, because they seem to develop normally in the
absence of MCL-1. However, MCL-1DM Mo-MS were more sen-
sitive to death compared to control Mo-MS within BM MS and
T cell cocultures (Figure 3A, B). Therefore, we hypothesized
expression of another antiapoptotic protein was being induced
to compensate for the loss of MCL-1. We performed gene-
expression studies in human and mouse MDSCs and observed
high mRNA expression of the MCL-1-related factor A1 (Figures
S2A–S2D). Like MCL-1, A1 is inhibited by the BH3-only protein
NOXA and couples to the BAX-BAKmitochondrial intrinsic death
pathway (Figure 3C). A1 gene expression is regulated by NF-kB,
and the short half-life of A1 protein is controlled posttranslation-
ally (Lee et al., 1999; Wang et al., 1999). We therefore reasoned
induction of A1 might sustain Mo-MS viability in the absence of
MCL-1 and investigated what factors promoted A1 expression.
GM-CSF was a strong inducer of A1 protein relative to TNF, IL-
1a, or IL-1b (Figure 3D) and rescued the viability of MCL-1DM
Mo-MS (Figure 3E). Therefore, GM-CSF is a key factor sustaining
A1 expression and regulates the viability of Mo-MDSCs in the
absence of MCL-1.
The Absence of MCL-1 Primes Mo-MS for Death
Our data raised the possibility that the viability of MCL-1DM
Mo-MS might be compromised when A1 inducing factors
were limiting. Therefore we determined whether sustained A1
expression was required to maintain the suppressive function
of Mo-MS in the absence of MCL-1. When we sorted MCL-
1DM or control C57BL/6 Mo-MS from BM cultures, we found
that MCL-1DM Mo-MS were more sensitive to death in the
absence of cytokines compared to control Mo-MS (Figure 3F;
Figure S2E). Viability was rescued only in the presence of GM-
CSF, presumably due to induction of A1 (Figure 3D; Figures
S2E and S2F). When MCL-1DM Mo-MS were used in T cell
suppression assays, we noted a striking reduction in their ability
to block CD8+ proliferation compared to control Mo-MS (Fig-
ure 3G) or the unsorted MCL-1DM Mo-MS cultures (Figure 1).
The mechanism involved rapid loss of viability of MCL-1DM
Mo-MS during T cell suppression assay (Figure 3A) causing an
apparent decrease in suppressive function. Therefore, MCL-
1DMMo-MS require continuous exposure to cytokines to sustain
A1 expression. These data also provide an explanation for the
survival of monocyte-lineage cells in the MCL-1DM mice, where
high circulating amounts of GM-CSF are likely enforcing A1
expression (Steimer et al., 2009).
In control Mo-MS cells ‘‘constitutive’’ MCL-1 expression
should be ‘‘dominant’’ to the effects of cytokine-regulated A1.
In other words, the absence of A1 alone should not affect Mo-
MS viability. To test this, we used a Vav-regulated shRNA system
to simultaneously deplete all three murine A1 isoforms in mouse
MDSC cultures (Ottina et al., 2012). As expected, A1-deficient
Mo-MS retained their suppressive effects, arguing that A1 isIrequired for sustaining the viability of MO-MDSCs, but not for
their suppressive function (Figures S2G and S2H).
Requirement for c-FLIP in Mo-MS Cannot Be Bypassed
A prediction from the experiments described above is Mo-MS
survive because they express sufficient c-FLIP and require
either MCL-1 or exogenous stimulation (GM-CSF) to induce
A1. What is the factor inducing c-FLIP? At multiple stages dur-
ing development, DR signaling induces c-FLIP as a regulatory
mechanism to suppress Caspase-8 and RIPK3 death. A candi-
date DR ligand regulating Mo-MS survival is TNF (Hu et al.,
2014; Sade-Feldman et al., 2013; Zhao et al., 2012). We there-
fore asked whether TNF induced the expression of c-FLIP in
Mo-MS. TNF and GM-CSF-treated Mo-MDSCs had increased
expression of c-FLIP and maintained A1 amounts similar to
GM-CSF-treated cells (Figure 4A). TNF + GM-CSF-treated
PMN-MDSCs expressed c-FLIP and MCL-1 and did not ex-
press A1 (Figure S3).
Given that TNF + GM-CSF treatment induced both A1 and
c-FLIP in Mo-MS, we next sought to determine whether A1 in
the absence of c-FLIP could maintain Mo-MDSC viability in
response to GM-CSF. To test this, we again used tamoxifen-
mediated Cre-deletion of c-FLIP in MS cultures using Cflarfl/fl;
Rosa-CRE-ERT2 mice (Figures 4B and 4C). In the absence
of c-FLIP, the viability of Mo-MS could not be restored by
GM-CSF (Figures 4B and 4C). Thus, in Mo-MS, A1 induction
by GM-CSF to inhibit the intrinsic death pathway cannot bypass
the absolute requirement for c-FLIP to inhibit the extrinsic
Caspase-8 death pathway. Together these data demonstrate
c-FLIP is the dominant survival factor for Mo-MS develop-
ment. However, development of Mo-MS also requires sufficient
expression of either MCL-1 or A1 to ensure their survival
(Figure 4).
Death Signaling and Immunosuppressive Function of
MDSCs in Cancer
We next sought to determine whether the death pathways con-
trolling in vitro-generated MS similarly regulated the survival of
MDSCs in malignancy. MDSCs accumulate in spleen, blood,
and local site of tissue damage as inflammation increases (Ga-
brilovich and Nagaraj, 2009; Gabrilovich et al., 2012; Ugel
et al., 2012). Several studies have demonstrated MDSCs have
different functional properties based on the tissue site they are
recovered from, and it is now clear that different signals control
MDSC development or expansion and acquisition of immuno-
suppressive function. However, an unexplored mechanism to
account for the role that different organ sites play in MDSC func-
tion is the acquisition of survival signaling. We therefore tested
how the anatomical site influences the suppressive function
and expression of death signaling inhibitors in MDSCs during
tumor growth. Bulk populations of splenic MDSC from control
or MCL-1DM mice bearing EG7 tumors were enriched for Mo-
MDSC and had stronger suppressive activity relative to controls
(Figures 5A and 5B). When the suppressive activity of MDSC
subsets isolated from the spleens (Figure 5C) or tumors (Fig-
ure 5D) of EG7 tumor bearing C57BL/6 mice was evaluated
we found suppressive activity was principally found in the
Mo-MDSC fraction (Figures 5C and 5D). Expression of death
inhibitors in Mo-MDSC isolated from spleens and tumors wasmmunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc. 951
Figure 3. A1 and MCL-1 Are Needed to Maintain the Survival of Mo-MS
(A and B) BM-MSwere grown fromC57BL/6 or MCL-1DMmice. The percentage of cell death wasmeasured by V405 staining of control or MCL-1DMMo-MS at d6
of BM-MS culture (top) or after 24 hr T cell suppression assay coculture (bottom). (B) Quantification of V405+ cells from the experiments representative in (A).
Data expressed as the mean ± the SD and are representative of two independent experiments. Statistical analysis with unpaired t tests was performed; *p% 05,
**p% 005.
(C) Diagram showing the role of A1 and MCL-1 in inhibiting the mitochondrial death pathway.
(D) Lysates from C57BL/6 MS cultures were subjected to immunoblotting for A1 following 24 hr stimulation with the cytokines shown, all at 50 ng/mL. GRB2
(26 kDa) was used as the loading control.
(E) The percentage of nonviable V405+ Mo-MS after stimulation with cytokines (50 ng/mL) is shown. Data expressed as the mean ± SD and are representative of
no less than three independent experiments (n = 2 samples for each experiment). Statistical analysis with unpaired t tests was performed; ****p% 0.0001.
(legend continued on next page)
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Figure 4. Exogenous Regulation of A1 Partially Rescues c-FLIP Loss
(A) BM-MS were grown from C57BL/6 mice. Mo-MS cell lysates were subjected to immunoblotting for the indicated targets following 24 hr stimulation with the
cytokines shown (ng/mL). GRB2 (26 kDa) was used as the loading control. Protein lysates from FLIPDMMS served as a specificity control for c-FLIP expression.
(B and C) BM-MS cultures from Cflarfl/fl Rosa-Cre-ERT2+ or Cflarfl/fl Rosa-Cre-ERT2 mice were treated with tamoxifen or ethanol as a control on D5 of BM
culture. (B) On day 6, Mo-MS were sorted and cultured with cytokines for 24 hr: GM-CSF (50 ng/mL), TNF (5 ng/mL). Viability was measured by V405 staining.
Representative histograms are gated on Ly6C+ cells. (C) Mo-MS were sorted and cultured with the indicated cytokines for 24 hr. The percentage of nonviable
V405+ cells in Mo-MS cultures was measured by flow cytometry. Data are expressed as the mean ± SD from one independent experiment and are representative
of two independent experiments (two mice per group). Statistical analysis with unpaired t tests was performed; ****p% 0.0001.
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spleen and tumor resident MDSCs, while c-FLIP and A1 expres-
sion were predominantly found in Mo-MDSCs isolated from the
tumor site (Figure 5E). Therefore, Mo-MDSC expressed the high-
est amount of antideath molecules at the tumor site, and consti-
tutive expression of c-FLIP and A1 distinguishes suppressive
tumor resident Mo-MDSC from their splenic counterparts (Fig-
ures 5C–5E).
Our data using the EG7 model demonstrate that Mo-MDSC
are the principle immunosuppressive MDSC population during
tumor growth. However, MDSC expansion and population
structure can be affected by the source of the primary tumor
(Gabrilovich et al., 2012). Therefore, we next asked whether
Mo-MDSC were the dominant immunosuppressive population(F) The percentage of nonviable V405+ Mo-MS was evaluated by V405 staining a
experiments). Quantification of data, expressed as the mean ± SD from one inde
**p% 0.005.
(G) Suppressive function of MS was measured using 5 3 105 CFSE-labeled OT-
dilution was evaluated by flow cytometry after 72 hr. Data are compiled from thr
Iof MDSCs in other transplantable tumor models. Mice bearing
Lewis lung carcinoma (LLC) or B16 melanoma (B16) tumors
had expanded populations of Mo- and PMN-MDSC in the
spleen and tumor (Figures S4A and S4B). Mo-MDSCs isolated
from EG7, LLC, and B16 tumors strongly inhibited T cell prolif-
eration whereas PMN-MDSCs isolated from EG7 or LLC tumors
failed to inhibit T cell proliferation (Figures 5D and 5F; Fig-
ure S4C). Evaluation of PMN-MDSC from B16 tumors was not
possible given the low number of PMN-MDSCs infiltrating these
tumors (Figure S4B). Further, tumor-resident Mo-MDSCs, but
not PMN-MDSCs, inhibited polyclonal T cell activation in vitro
(Figure 5G). Taken together, these data identify Mo-MDSC as
the principle immunosuppressive population of MDSCs during
cancer.fter 24 hr stimulation with the indicated cytokines (ng/mL) (n = 3 independent
pendent experiment. Statistical analysis with unpaired t tests was performed;
I cells cocultured with titrated MS in the presence of SIINFEKL peptide. CFSE
ee independent experiments and are presented as mean ± SD.
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Figure 5. Suppressive Function and En-
hanced Expression of Antiapoptotics Distin-
guishes Mo-MDSC at the Tumor Site
(A) MDSC populations in control and MCL-1DM
mice bearing EG7 tumors. Contour plots show
spleen CD11b+-gated MDSCs. Data are repre-
sentative of three independent experiments (n = 2
mice per group).
(B) The suppressive activity of spleen MDSC
populations isolated from EG7 tumor-bearing
mice. Data are representative of three independent
experiments. Percent suppression is calculated as
described in the methods. Statistical analysis with
unpaired t tests was performed; **p% 01.
(C and D) MDSCswere isolated from the spleen (C)
or tumor (D) of EG7 tumor bearing C57BL/6 mice.
Suppressive activity of Mo and PMN-MDSCs was
evaluated by CFSE dilution in CD8+ OT-I T cells in
the presence of SIINFEKL and titrated MDSCs. (D)
Statistical analysis with unpaired t tests was per-
formed; *p < 0.01, ****p < 0.0001.
(E) Protein expression in freshly isolated spleen
and tumor Mo-MDSCs from EG7-bearing mice. An
asterisk indicates a band reactive to anti-c-FLIP
antibodies not present in the FLIPDM negative
control that might represent an alternative isoform
or processed c-FLIP product.
(F) Suppressive function of tumor resident MDSCs
using 53 105 CFSE-labeled OT-I cells with 43 105
(green), 2 3 105 (orange), 1 3 105 (purple) MDSCs
with SIINFKEL peptide (gated on CD8+ cells).
Cascade plots from two experiments are shown
(n = 5–8 for each experiment).
(G) The ability of tumor resident Mo and PMN-
MDSCs to inhibit polyclonal T cell proliferation was
evaluated by monitoring CFSE dilution. Repre-
sentative data from three independent experi-
ments are shown (gated on CD8+ cells).
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MDSCs
We reasoned that ablation of the nonsuppressive PMN-MDSC
subset using the MCL-1DM background would have minimal
effects on tumor growth. To test this, we used the TH-MYCN
genetic model of neuroblastoma where elevated numbers of
MDSCs accumulate in the blood and spleen (Weiss et al.,
1997). We created MCL-1DM; TH-MYCN mice and screened for
tumors in the kidney-adrenal region by ultrasound imaging (Teitz
et al., 2011). Neuroblastoma+ mice on the MCL-1DM background
had lowered numbers of PMN-MDSCs, and a relative enrich-
ment of Mo-MDSCs in both the blood and spleen (Figure 6A).
The absence of PMN-MDSCs and other granulocytes on the
MCL-1DM background did not affect tumor incidence, patho-
logical appearance (Figure 6B), and tumors had intratumoral
macrophage numbers equivalent to TH-MYCN+ mice of the
same genetic background (Figure 6C). The growth rate of tu-
mors was not significant between genotypes. As noted above954 Immunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc.MCL-1DM mice have high circulating
amounts of GM-CSF, which by virtue of
A1 regulation might account for the
apparent normal numbers of monocytes
and their progeny (Steimer et al., 2009).To further examine the functional role of PMN-MDSCs, we
used Ccr2/ mice. In these animals, the recruitment of mono-
cytes to inflammatory sites is severely impaired (Ginhoux and
Jung, 2014). MDSCs isolated from spleens and tumors of
CCR2-deficient mice were enriched for PMN-MDSC (Figures
6D–6F). Although Ccr2/ mice had a small population of
Ly6G Ly6C+ cells, they were predominately granulocytic and
were unable to inhibit T cell proliferation (Figures 6E and 6F).
Only Mo-MDSC isolated from WT mice contained a functionally
suppressive population of Mo-MDSC (Figures 6E and 6F).
Collectively, these data demonstrate that Mo-MDSCs are the
main immunosuppressive MDSC population within the tumor
microenvironment.
DISCUSSION
Our data establish the underlying hierarchy of survival signaling
required for myeloid suppressors: Mo-MS require either MCL-1
Figure 6. PMN-MDSCs Do Not Influence Tumor Incidence In Vivo and Are Not Immunosuppresive
(A) Representative flow plots of MDSC populations in neuroblastoma+ MCL-1DMmice. Contour plots from blood (top) or spleen (bottom) gated on CD11b+ cells.
(B) Cumulative tumor incidencemeasured by ultrasound imaging inMCL-1DM (n = 43) or control mice (n = 38) (tumor incidence is20%–30% in TH-MYCN+mice).
All mice were generated fromMcl1fl/+; LysM-Cre+; TH-MCYN+ intercrossed housed in the same rack. All mice were screened beginning at 7–8 weeks after birth
and screened for 7 consecutive weeks. Tumor incidence between the strains shows no differences (p = 0.1139, Wilcoxon rank sum test).
(C) Macrophage density inside neuroblastomas. Paraffin sections were stained with anti-Mac2 (red) to visualize macrophages.
(D–F) EG7 tumors were implanted in Ccr2/ or WT control mice. (D) Phenotypic analysis of MDSC populations in the spleen (top) and tumor (bottom). Plots are
gated on CD11b+ cells (E and F). Mo and PMN-MDSCs were isolated from tumor tissue as shown in (D). Cytospins of sorted MDSC fractions (top panels) and
CFSE dilution in CD8+ OT-I cells (bottom panels) cultured in the presence or absence of 2 3 105 Mo and PMN-MDSCs.
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Control of Myeloid Suppressors by Death Pathwaysor A1 and have an absolute requirement for c-FLIP to inhibit
caspase-8 mediated apoptosis. By contrast, PMN-MS require
MCL-1, and probably A1 (Ottina et al., 2012), but are completely
independent of death regulation by c-FLIP.
Our results argue that viability of MS influences suppression
assays. For example, TNF was linked with increased suppres-Isive capacity of MDSCs (Sade-Feldman et al., 2013; Zhao
et al., 2012). In our hands, TNF induces c-FLIP expression as
long as the suppression of the intrinsic death pathway is simulta-
neously engaged by MCL-1 or A1, providing a mechanistic
explanation for suppression: we predict that sufficient c-FLIP
expression will prolong the viability of Mo-MS or Mo-MDSCs inmmunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc. 955
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cocultures. The same concept can be extended from our in vivo
findings tracking c-FLIP, A1, and MCL-1 expression in tumor-
bearing mice where both c-FLIP and A1 are increased at the
tumor site, likely extending their viability in the tumor microenvi-
ronment where necrosis, hypoxia, and cell debris are present.
Therefore, our data have implications in cancer if the objective
is to reduce the number and activity of myeloid suppressors:
either c-FLIP or A1/MCL-1 must be targeted to weaken the
most suppressive cells.
The role of c-FLIP expression in the monocytic compartment
requires further evaluation because it remains unclear when
and how c-FLIP is induced to counteract DR-death inducing
signaling in the BM. One model is tonic signaling from TNFRs
in the BM that induces sufficient c-FLIP to protect from DR
signaling from FAS and allow maturation of monocytic cells.
However, Mo-MDSCs in the inflammatory site are associated
with increased c-FLIP expression, resulting in increasing resis-
tance to DR signaling from excessive TNF or possibly TRAIL,
and results in enhanced viability (Condamine et al., 2014). How-
ever, because the lifespan of monocytic cells in inflammatory
sites is limited, and monocytic cells continuously reseed unre-
solved inflammatory sites, Mo-MDSCs are likely subject to a
multitude of signals that exogenously regulate c-FLIP and A1,
limiting or extending their lifespan accordingly.
Our experiments provide guidance on controversial aspects of
MDSC subsets and their immunosuppressive activity. Mono-
cytic lineage cells are the dominant immunosuppressive popula-
tion of MDSCs. Furthermore, these data provide a rationale for
using our genetic platform approach to revisit unresolved as-
pects of MDSC function. For example, the role of the PMN-
MDSCs, which are produced in some tumor models in excess
of monocytic MDSCs, are poorly understood (Youn et al.,
2012). Part of this confusion might arise from the heterogeneity
of PMN-MDSC studied. In cancer patients, sorted PMN-MDSCs
as defined by CD115+, DRlo cells commonly contained mono-
cytic cells (Vasquez-Dunddel et al., 2013). In our hands, PMN-
MS and PMN-MDSCs have no suppressive capacity toward
T cells and these data are supported by showing that loss of
granulocytes did not influence the outcome of neuroblastoma
development. We note that other studies have documented
T cell suppressive effects of PMN-MDSCs (Movahedi et al.,
2008; Schouppe et al., 2013; Youn et al., 2012), along with anti-
tumor effects caused by depleting granulocytic cells with anti-
Gr-1 or anti-Bv8 antibodies (Kowanetz et al., 2010; Srivastava
et al., 2012). However, our genetic models offer the advantage
of separating the Mo- and PMN- MDSC lineages in a more
thorough manner than previously possible, and when coupled
with antibody depletion studies, a more precise picture of
the contribution of myeloid subtypes to cancer can be gained.
In addition, issues of antibody specificity toward a particular
MDSC can be established with greater certainty, given that
many surface molecules of myeloid cells, like Gr-1, are ex-
pressed on other cells of the immune system. This point is
further illustrated by our data showing that Ly6G Ly6C+ granu-
locytes contaminateMo-MDSC sorting gates due to overlapping
surface-marker expression. PMN-MDSC might also have func-
tions beyond T cell suppression (Kowanetz et al., 2010; Ryan
et al., 2013). One alternative explanation is that PMN-MDSCs956 Immunity 41, 947–959, December 18, 2014 ª2014 Elsevier Inc.are produced as a consequence of deregulated hematopoiesis
and are ‘‘bystanders.’’ Collectively, the role of PMN-MDSCs in
cancer and other forms of nonresolving inflammation remains
unclear but based on our findings can be elucidated using the
genetic platforms we have established.
The segregated requirement for the activity of c-FLIP in Mo-
MS and Mo-MDSCs but their granulocytic counterparts was un-
expected because both cell types originate from the common
myeloid progenitor (CMP). Our data suggest the requirement
for c-FLIP is acquired at some point after theCMPbecause gran-
ulocytic cells are independent of c-FLIP. Therefore, a ‘‘branch
point’’ in myeloid lineage development exists where c-FLIP
expression becomes important for one branch but not the other.
This concept can be extended to interrogate the timing and
strength of signal from DR receptors during myeloid develop-
ment, because signaling from FAS, TRAIL, or TNF receptors in
the absence or low amounts of c-FLIP would induce death (Perl-
man et al., 1999). Therefore, one or more signals must induce c-
FLIP in monocytic precursors to ensure survival, while further
enforcement of c-FLIP expression, as we found in the tumor
versus spleen Mo-MDSCs, would increase viability.
An additional implication of the requirement for c-FLIP in Mo-
MDSCs and their monocytic precursors comes from in vivo use
of chemotherapy drugs. Several chemotherapy agents cause a
selective depletion of monocytic cells, including gemcitabine
and trabectadin (Germano et al., 2013; Ugel et al., 2012). As
the latter was linked with TRAIL-mediated death, it suggests
that chemotherapy drugs might affect c-FLIP expression in
monocytic cells directly or indirectly. When cells with low c-
FLIP encounter a DR signal, their viability is compromised.
Therefore, one way to weaken Mo-MDSCs would be to exoge-
nously adjust the ability of cells to express c-FLIP to protective
amounts, while exposing them to DR signaling. Our data provide
new insights that will help direct development of treatments for
nonresolving inflammation wherein the survival of immunosup-
pressive MDSCs can be modulated to eliminate them during




C57BL/6, Ccr2/, and OT-I mice were obtained from The Jackson Labora-
tory, Mcllfl/fl and Cflarfl/fl mice were bred to the LysM-Cre deleter (B6.129P2-
Lyz2tm1(cre)Ifo/J), and the specific alleles used here were reported (Huang
et al., 2010; Steimer et al., 2009). TH-MYCN mice were screened for tumors
by weekly ultrasound imaging (Teitz et al., 2011; Weiss et al., 1997). Deletion
of c-FLIP or MCL-1 was confirmed for all mice by flow cytometry of the blood
(for CD11b and Ly6C/Ly6C) or by immunoblot. RIPK3 and FADD-deficient
mice and their compound crosses have been described (Dillon et al., 2012;
Weinlich et al., 2013). Mice bearing shRNAs against all A1 isoforms were pub-
lished previously (Ottina et al., 2012). All mice in this study were used accord-
ing to protocols approved by the Institutional Animal Care and Use Committee
at St. Jude Children’s Research Hospital.
Flow Cytometry
Single cell suspensions were blocked with normal mouse serum (1:10) for
5 min at room temperature and were then stained with antibodies at 1:100 di-
lutions. Pacific blue anti-mouse CD11b, APC anti-mouse Ly6C, APC anti-
mouse CD8, and PE anti-mouse Ly6G were purchased from BioLegend.
Viability was assessed using a LIVE/DEAD fixable dead cell stain kit (Invitro-
gen). V405 staining was performed according to the manufacturer’s protocol
Immunity
Control of Myeloid Suppressors by Death Pathwaysand analyzed on APC+ Mo-MDSC populations. Flow analysis was performed
on a FACS Canto II and data were analyzed using FlowJo software. Sorting
was performed using an iCyte Reflection system.
OT-I T Cell Suppression Assays
Lymph node cells from OT-I transgenic mice were labeled with 5 mM CFSE,
washed, and added to all wells at 5 3 105 cells per well. SIINFEKL peptide
(1 mg/ml final concentration) was added to all culture wells except for nega-
tive control wells. MS or MDSCs from individual mice were resuspended at
8 3 106 cells/ml and step two dilutions were made starting at a concentration
of 4 3 105 cells per well. As a negative control 5 3 105 OT-I cells were
cultured with RPMI only. As a positive control, 5 3 105 OT-I cells were
cultured with 1 mg/ml SIINFEKL peptide. Proliferation was measured after
72 hr by flow cytometry. To evaluate suppression of proliferation, we gated
plots on CD8+ cells and the percentage of cells that had diluted CFSE was
evaluated using FlowJo. The percentage of proliferating cells was then
used to calculate the percent suppression of proliferation as described
below. In some experiments, MCL-1 and c-FLIPDM cells were mixed at vary-
ing ratios to obtain a constant number (2 3 105) of input MS cells per well.
Percent suppression of proliferation was calculated using the following
formula: 1 (% proliferation with MDSCs/% proliferation without MDSCs) 3
100. In some experiments, bromodeoxyuridine (BrdU) incorporation into
CD8+ cells was used to measure proliferation. Staining for BrdU and flow
analysis was performed with standard techniques.
Polyclonal T Cell Suppression Assays
Lymph node cells from C57BL/6 mice were labeled with 5 mMCFSE, washed,
and added to all wells at 5 3 105 cells per well. Cells were stimulated with
plate-bound anti-CD3 (0.5 mg/ml) and soluble anti-CD28 (3 mg/ml) both pur-
chased from eBioscience. Proliferation of CD8+ cells was evaluated by flow
cytometry after 72 hr. Plots are gated on CD8+ cells.
Tumor Models
For EG7 tumor studies, 3 3 106 EG7 cells were injected subcutaneously in
the rear flank of C57BL/6 or MCL-1DM mice. 1 3 106 LLC cells and 1.5 3
106 B16 cells were injected onto the flank of C57BL/6 mice. Twelve to fourteen
days after tumor implantation, mice were sacrificed and spleens and tumors
were collected. MCL-1DM were crossed to a TH-MYCN+ background (Teitz
et al., 2011; Weiss et al., 1997) and further backcrossed to a 129 background.
Tumor incidence was measured by ultrasound imaging on mice treated with
Nair to remove abdominal hair each week for 7 consecutive weeks. Tumors
were scored positive at a minimum size of 10 mm3 and were removed from
study if the tumor size equaled or exceeded 500 mm3.
Isolation of Myeloid Cells from Tumor-Bearing Mice
CD11b+ tumor-associated myeloid cells were isolated from mouse tumors by
mincing tumor tissue and placing it in dissociation media (1 mg/ml DNase,
2.5 mg/ml collagenase P, 2.5 mg/ml collagenase/dispase, 20 ml/ml B27,
10 ml/ml N2, 1 mL neural basal medium) for 20 min at 37C with gentle shaking
for digestion. The cell/tissue suspension was then manually dissociated by re-
suspending the cell/tissue pellet in a DNase solution (0.5 mg/ml DNase, 1 ml
b-mercaptoethanol, 8 ml glucose 45%), pipetted up and down through a
10 ml pipette and passed through a 70 mM strainer. Cells were washed and
collected at the 35%–60% fraction of a Percoll gradient followed by CD11b+
MACS separation. CD11b+ cells were then stained with antibodies against
Ly6G and Ly6C and further purified by cell sorting as described above. To
purify spleenMDSCs, we prepared single-cell suspensions from spleens of tu-
mor-bearing mice. Cells were blocked with 10% normal mouse serum in
MACS buffer for 10 min on ice. In some experiments, MDSCs were purified
by first performing a Ly6G+ cell depletion followed by enriching for Ly6C+ cells
as described (Dolcetti et al., 2010). For other experiments, MDSCs were iso-
lated from spleens by CD11b+ MACS separation followed by staining with an-
tibodies against Ly6G and Ly6C and further purification by cell sorting as
described above.
Statistical Analysis
Two-tailed Student’s t test was used for evaluating statistical significance be-
tween groups. Fisher’s exact test was used to estimate differences in tumorIappearance between WT mice and MCL-1DM mice on a TH-MYCN back-
ground. Wilcoxon Rank Sum was used for tumor volume analysis.
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